Cell permeable, reversible, potent and specific inhibitor of phosphoinositide 3-kinase (IC50=17nM for PI(3)K p110β, IC50=53nM for PI(3)K p110γ and IC50=6nM for PI(3)K p110δ). Blocks cellular PI(3)K/Akt (PKB) signalling in vitro and inhibits Akt(PKB)-dependent tumor growth in mice in vivo without significant toxic effect. More effective than LY 294,002 (Prod. No. BML-ST420) in vitro and as in vivo.
Product Details
| Alternative Name: | 2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine |
| |
| Formula: | C19H21F2N7O2 |
| |
| MW: | 417.4 |
| |
| CAS: | 475110-96-4 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by EM-MS and NMR. |
| |
| Appearance: | White powder. |
| |
| Solubility: | Soluble in DMSO (21mg/ml). Sparingly soluble in ethanol (<1mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stock solutions are stable for up to 6 months when stored at -20°C. |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor: S. Yaguchi, et al.; J. Natl. Cancer Inst.
98, 545 (2006),
Abstract;
A novel phosphatidylinositol 3-kinase inhibitor, ZSTK474 exerted antitumor activity against human tumor xenografts by oral administration: S. Yaguchi, et al.; Proc. Am. Assoc. Cancer Res.
46, 1691 (2005),
Abstract;
Related Products
